Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy products for patients with compromised pulmonary function. Its core product references include the SmartVest Airway Clearance System, which combines a programmable air pulse generator, therapy garment, and connecting hose for airway clearance therapy.
Recurring ELMD news centers on quarterly financial results, revenue trends in homecare, hospital, distributor, and other channels, operating leverage, manufacturing and sales-efficiency updates, share repurchase authorizations, and investor conference participation. Company updates also discuss bronchiectasis-focused market education and the role of SmartVest within Electromed's pulmonary-care business.
Electromed (ELMD) will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14-16, 2026, with President and CEO Jim Cunniff presenting at 3:30 ET on Monday, September 14. Management will also hold one-on-one investor meetings. The company will attend the LD Micro 20th Annual Main Event in Los Angeles on October 19-21, 2026, where Cunniff will present and host additional one-on-one meetings. Live webcast links for both presentations will be available on Electromed’s website under “Events & Presentations | SmartVest.”
Electromed (NYSE American: ELMD) announced that President and Chief Executive Officer Jim Cunniff plans to retire on or about April 2, 2027, and will also step down from the board at that time. The board has begun a national search for his successor and engaged an executive search firm. Cunniff, who has led the company and served as a director since 2023, is credited by Electromed with consistent double-digit net revenue growth, operating margin expansion, and 15 consecutive quarters of year-over-year revenue and profit growth. He plans to work with the board and leadership team to support a smooth transition.
Electromed (NYSE American: ELMD) reported record results for Q4 FY 2026 and the full year ended June 30, 2026. Q4 net revenue rose 11.6% to $19.4 million, operating income grew 25.8% to $3.8 million (19.7% margin), and net income increased 54.3% to $3.4 million, or $0.39 per diluted share.
For FY 2026, net revenue increased 15.3% to $73.8 million, driven by 16.3% growth in direct homecare revenue to $66.6 million. Operating income rose to $13.9 million (18.8% of net revenues), while net income reached $11.3 million, or $1.30 per diluted share. Electromed ended the year with $20.5 million in cash, no debt, operating cash flow of $9.7 million, and repurchased $3.9 million of its common stock.
Electromed (NYSE American: ELMD) plans to release its fiscal 2026 fourth quarter financial results, for the period ended June 30, 2026, on Tuesday, August 25, 2026, after the U.S. stock market closes.
Company management will hold a conference call the same day at 5:00 p.m. Eastern Time to review and discuss the results. Investors can join by dialing (877) 407-3982 (toll-free) or (201) 493-6780. A live webcast will be available in the Investor Relations section of Electromed’s website through the “Electromed Fiscal Q4 2026 Earnings Call” link. For those unable to listen live, a telephone replay can be accessed at (844) 512-2921 (toll-free) or (412) 317-6671 using Access ID 13761827, and a webcast replay will also be posted under Events & Presentations on the company’s Investor Relations page.
Electromed (NYSE American: ELMD) reported record Q3 FY 2026 results for the period ended March 31, 2026. Net revenues rose 18.4% to $18.6 million, driven by 18.6% growth in direct homecare revenue. Operating income increased 76.0% to $3.8 million (20.3% margin).
Net income grew 58.8% to $3.0 million, or $0.35 per diluted share. Gross margin improved to 78.8%. Electromed ended the quarter with $17.0 million in cash, no debt, $40.0 million in working capital, and $49.2 million in shareholders’ equity, after repurchasing $3.9 million of stock year-to-date.
Electromed (NYSE American: ELMD) will release fiscal 2026 third-quarter results for the period ended March 31, 2026, on May 12, 2026 after market close. Management will host a conference call the same day at 5:00 p.m. ET with a live webcast available in the Investor Relations section. Replay dial-in numbers and a webcast replay will be posted for later access.
Electromed (NYSE: ELMD) reported record Q2 FY2026 results for the three months ended December 31, 2025, with net revenues of $18.9M (+16.3% YoY), operating income $3.6M (+42.4% YoY), and net income $2.8M ($0.32 diluted EPS, +40.3% YoY). Homecare revenue led growth, rising 18.4% to $17.3M.
The company repurchased common stock ($2.8M in Q2; $3.8M six months), finished the quarter with $13.8M cash, no debt, and $45.4M equity.
Electromed (NYSE American: ELMD) will report fiscal 2026 second quarter results for the period ended December 31, 2025 on Tuesday, February 10, 2026 after market close. Management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.
Investors may join by phone at (844) 826-3033 (Domestic) or (412) 317-5185 (International), or listen via the live webcast in the Investor Relations section of Electromed's website. Replays will be available by phone at (844) 512-2921 (Domestic) or (412) 317-6671 (International) using Access ID 10206198, and via the Investor Relations Events & Presentations page.
Electromed (NYSE American: ELMD) will present at NobleCon21, Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, on Wednesday, December 3, 2025 at Florida Atlantic University in Boca Raton, Florida.
Jim Cunniff, Electromed's President and Chief Executive Officer, will present at 5:00 PM ET. A video webcast of the presentation will be available the following day on Electromed's Events & Presentations page and on the Noble Capital Markets conference catalog at www.nobleconference.com.
Electromed (NYSE American: ELMD) reported Q1 FY 2026 results for the three months ended September 30, 2025, with net revenues up 15.1% to $16.9M and net income up 44.9% to $2.1M ($0.25 diluted EPS). Operating income rose 37.8% to $2.7M. Homecare revenue was $14.9M; hospital revenue grew 51.7% to $1.047M and distributor revenue rose 41.2% to $829K. Gross profit was $13.2M (78.1% of sales). The board approved a $10M stock repurchase authorization. As of September 30, 2025, cash was $14.1M, accounts receivable $24.8M, no debt, working capital $35.8M, and shareholders’ equity $44.7M.
Management completed a manufacturing optimization plan and implemented a new CRM to boost sales productivity.